Japanese Amitiza Launch Provides Immediate Upside For Sucampo Pharmaceuticals
December 11, 2012
Sucampo Pharmaceuticals (SCMP) has announced that its commercialization partner for Japan, Abbott Labs (ABT), recorded the first sale in the country of Sucampo's prescription treatment for chronic constipation, Amitiza, resulting in a $15 million milestone payment to Sucampo. That $15 million in cash is equivalent to $0.36 per share, an immediate addition to SCMP's balance sheet that should, in theory, improve the stock's value by roughly 8% from Monday's close.
いろいろ動きそうな予感が・・・・・
2012/12/12 02:35
Japanese Amitiza Launch Provides Immediate Upside For Sucampo Pharmaceuticals
December 11, 2012
Sucampo Pharmaceuticals (SCMP) has announced that its commercialization partner for Japan, Abbott Labs (ABT), recorded the first sale in the country of Sucampo's prescription treatment for chronic constipation, Amitiza, resulting in a $15 million milestone payment to Sucampo. That $15 million in cash is equivalent to $0.36 per share, an immediate addition to SCMP's balance sheet that should, in theory, improve the stock's value by roughly 8% from Monday's close.